PD-L1 expression was observed in 47% and 16% of tumors, respectively, and the PD-L1 expression (≥ 5%) was not concurrently associated with high levels of CD8 + TILs (observed in only 1 pretreatment and 5 resistant EGFR-mutant tumor samples but not observed in any ALK-positive, pre- or post-TKI tissues). This evidence concerns the gene CD274 and neoplasm.